Indivior PLC (IZQVF) Research

Indivior PLC, along with its various associated companies, focuses on the creation, production, and distribution of buprenorphine-derived prescription pharmaceuticals. These medications are primarily utilized in the management of opioid addiction and concurrent mental health disorders. The firm's ongoing product development initiatives are geared towards advancing therapies for opioid use disorder, other forms of addiction, and schizophrenia. Among its prominent offerings, Indivior actively commercializes SUBLOCADE, an injectable treatment administered subcutaneously, and a range of sublingual formulations, including SUBOXONE (available as both a film and a tablet) and SUBUTEX (a tablet). The company also continues to sell established legacy products such as Temgesic, Burpex, and Buprenex. With a global presence, Indivior PLC operates in roughly 40 countries worldwide. The company maintains a research partnership with Addex Therapeutics Ltd. Founded in 2014, Indivior PLC's main corporate office is located in North Chesterfield, Virginia.

Open Indivior PLC (IZQVF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.